Cirtuvivint + Irinotecan for Small Cell Lung Cancer

This trial explores whether adding cirtuvivint, a new drug, to the chemotherapy drug irinotecan can help treat small cell lung cancer (SCLC) that has returned after treatment. Researchers aim for this combination to increase cancer cells' sensitivity to treatment, improving response and delaying cancer progression. Individuals treated for SCLC who have experienced a recurrence may be suitable for this study, particularly if their previous treatment ceased to be effective. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug combination.

The trial does not specify if you need to stop all current medications, but you cannot use drugs that strongly affect CYP3A4, like ketoconazole or rifampin, within 10 days before starting the study medication.

Research shows that cirtuvivint, when combined with irinotecan, is under study for its safety and effectiveness in treating small cell lung cancer (SCLC). Cirtuvivint targets specific proteins that aid cancer cell growth. Early lab studies showed promise in stopping tumor growth and enhancing cancer cells' responsiveness to chemotherapy.

Currently, clinical trials are testing cirtuvivint to better understand its safety in humans. The early trial stages focus on patient tolerance and identifying possible side effects. Although detailed safety information is still being gathered, this phase suggests careful monitoring of safety before broader testing.

Researchers are excited about Cirtuvivint combined with Irinotecan for treating small cell lung cancer because this combination targets the cancer in a unique way. Unlike traditional treatments like chemotherapy, which broadly attacks rapidly dividing cells, Cirtuvivint is a novel agent that specifically disrupts the Wnt signaling pathway, a crucial process that many cancer cells rely on to grow. By combining this with Irinotecan, a well-established chemotherapy drug, the treatment aims to enhance cancer cell death while potentially reducing damage to normal cells. This targeted approach could lead to more effective and less toxic treatment options for patients.

This trial will evaluate the combination of cirtuvivint and irinotecan for treating small cell lung cancer (SCLC) that has returned after initial treatment. Research has shown that this combination targets specific proteins that aid cancer cell growth. Lab studies demonstrated that blocking these proteins halted tumor growth and increased cancer cells' responsiveness to chemotherapy. Although human studies remain limited, early results for this combination are promising in improving treatment response and slowing disease progression. Participants in this trial will receive both cirtuvivint and irinotecan as part of the study treatment.¹²³⁴⁵